Baseline Exposure to Antipsychotic Medication in Young People at Clinical High Risk for Psychosis: A 2‐Year Italian Follow‐Up Study
Human Psychopharmacology: Clinical and Experimental · 2025
DOI: 10.1002/hup.70003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, 2025. Verfasst von Lorenzo Pelizza und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - Università di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Antipsychotic Agents, Psychotic Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Progetto Esordi Psicotici della Regione Emilia Romagna.
Abstract (Originalsprache)
Objective
Despite various models examining baseline factors, predicting outcomes in individuals at clinical high risk for psychosis (CHR‐P) remains challenging. Specifically, neglecting factors like ongoing antipsychotic (AP) medications introduce bias and reduce method precision. The main aim of this research was to determine if the presence of AP prescription at baseline identifies a CHR‐P subgroup with worse prognostic outcomes over a 2‐year period.
Methods
A group of 180 FEP individuals (92 CHR‐P/AP+, 88 CHR‐P/AP−) were evaluated at baseline and after 24 months using the PANSS and GAF scales. Individuals with baseline AP prescription were included in the CHR‐P/AP+ subgroup; those not taking APs were grouped as CHR‐P/AP−. Univariate Cox regression analysis and mixed‐design ANOVA were performed.
Results
After 2 years, CHR‐P/AP+ had a higher rate of new hospitalization but lower rate of service disengagement. No significant inter‐group difference in psychosis transition rate was found. A “time‐×‐group” interaction effect on longitudinal improvement in PANSS total score was observed in CHR‐P/AP+ subjects.
Conclusions
It is advisable to conduct a more extensive outcome evaluation beyond the psychometric criteria for CHR‐P and the mere consideration of psychosis transition. Such an approach would facilitate the identification of specific CHR‐P subgroups with divergent prognoses and different AP response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - Università di Bologna, Bologna, Italy.
- Department of Mental Health and Pathological Addiction, Azienda USL di Parma, Parma, Italy.
- Pain Therapy Service, Department of Medicine and Surgery, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
ORCID-Profile: Lorenzo Pelizza
Förderung
- Progetto Esordi Psicotici della Regione Emilia Romagna
Zitieren
APA
Pelizza, L., Di Lisi, A., Leuci, E., Quattrone, E., Palmisano, D., Pupo, S., Pellegrini, P., & Menchetti, M. (2025). Baseline Exposure to Antipsychotic Medication in Young People at Clinical High Risk for Psychosis: A 2‐Year Italian Follow‐Up Study. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.70003
Vancouver
Pelizza L, Di Lisi A, Leuci E, Quattrone E, Palmisano D, Pupo S, et al. Baseline Exposure to Antipsychotic Medication in Young People at Clinical High Risk for Psychosis: A 2‐Year Italian Follow‐Up Study. Human Psychopharmacology: Clinical and Experimental. 2025. doi:10.1002/hup.70003
BibTeX
@article{Pelizza2025,
author = {Pelizza, Lorenzo and Di Lisi, Alessandro and Leuci, Emanuela and Quattrone, Emanuela and Palmisano, Derna and Pupo, Simona and Pellegrini, Pietro and Menchetti, Marco},
title = {Baseline Exposure to Antipsychotic Medication in Young People at Clinical High Risk for Psychosis: A 2‐Year Italian Follow‐Up Study},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2025},
doi = {10.1002/hup.70003}
}
EUVIMED